|
|
Volumn 294, Issue 16, 2005, Pages 2014-2015
|
|
European researchers, drug companies join forces against rare diseases
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NITISINONE;
ORPHAN DRUG;
AMYOTROPHIC LATERAL SCLEROSIS;
ATAXIA TELANGIECTASIA;
CLINICAL FEATURE;
CORNEA ULCER;
DRUG COST;
DRUG CYTOTOXICITY;
DRUG DESIGN;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG INFORMATION;
DRUG LEGISLATION;
DRUG MANUFACTURE;
DRUG RESEARCH;
DRUG SCREENING;
GENETIC DISORDER;
HUMAN;
INFORMATION SERVICE;
MEDICAL ASSESSMENT;
NONHUMAN;
NOTE;
PATHOPHYSIOLOGY;
PRIORITY JOURNAL;
PROGERIA;
RARE DISEASE;
TYROSINEMIA;
ARTICLE;
COOPERATION;
EUROPE;
INTERDISCIPLINARY COMMUNICATION;
ORGANIZATION;
ORGANIZATION AND MANAGEMENT;
ACADEMIES AND INSTITUTES;
COOPERATIVE BEHAVIOR;
EUROPE;
HUMANS;
INTERDISCIPLINARY COMMUNICATION;
ORPHAN DRUG PRODUCTION;
PRIVATE SECTOR;
PUBLIC SECTOR;
RARE DISEASES;
|
|
EID: 27244454931
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.294.16.2014 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|